Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Computable Name: | ||||
version: 2
ArtifactPublicationStatus: Active
url: https://fevir.net/resources/Evidence/6513
identifier: FEvIR Object Identifier/6513
name: OSFPreprint_PrimaryOutcomeMeasure_0_OG000
title: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Nigella Sativa Oil in Nigella Sativa for COVID-19 OSF Preprint
status: Active
date: 2021-07-20 08:52:18+0000
author: Brian S. Alper:
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
variableDefinition
description:
Nigella Sativa Oil (NSO)
note:
intervention group within study population: Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia.
variableRole: Population
observed: supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care
variableDefinition
description:
proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization
variableRole: Outcome
statistic
description:
There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001).
statisticType: Count of Participants
quantity: 37 Participants
SampleSizes
KnownDataCount 47 AttributeEstimates
Type Quantity Percentage 79 %